Cargando…

The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy

OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Miao‐Fang, Guan, Mei‐Mei, Liu, Chang‐Hao, Wu, Jie‐Ying, Rao, Qun‐Xian, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718550/
https://www.ncbi.nlm.nih.gov/pubmed/31310455
http://dx.doi.org/10.1002/cam4.2414
_version_ 1783447742619582464
author Wu, Miao‐Fang
Guan, Mei‐Mei
Liu, Chang‐Hao
Wu, Jie‐Ying
Rao, Qun‐Xian
Li, Jing
author_facet Wu, Miao‐Fang
Guan, Mei‐Mei
Liu, Chang‐Hao
Wu, Jie‐Ying
Rao, Qun‐Xian
Li, Jing
author_sort Wu, Miao‐Fang
collection PubMed
description OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical cancer (LACC). METHODS: Data of 347 LACC patients were retrospectively reviewed. Receiver operating characteristic (ROC) curves were constructed, and areas under the curves (AUCs) were compared to evaluate the ability to predict complete response (CR) following NACT. Patients were stratified into groups with low and high levels of SCCA and FBG and combined into low‐ or high‐SCCA and low‐ or high‐FBG groups. Cox regression analysis was performed to identify determinants of recurrence‐free survival (RFS) and overall survival (OS). RESULTS: The AUCs were 0.70, 0.68, and 0.66 for SCCA, FBG, and a combination of SCCA and FBG for predicting CR following NACT, respectively; however, the differences among AUCs were not significant (P = .496). Pretreatment SCCA and FBG levels were identified as independent predictors of RFS and OS. The high‐SCCA/high‐FBG group showed significantly worse prognosis than the low‐SCCA/low‐FBG group. After adjusting for other variables, high‐SCCA/high‐FBG remained independently associated with an increased risk of tumor recurrence and death. CONCLUSION: SCCA, FBG, and a combination of SCCA and FBG could acceptably predict CR following NACT. Pretreatment SCCA and FBG levels were independent prognostic factors. The combination of SCCA and FBG levels refined the prognostic stratification of LACC patients, which allowed the group of patients with the highest risk of recurrence and death to be identified.
format Online
Article
Text
id pubmed-6718550
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67185502019-09-06 The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy Wu, Miao‐Fang Guan, Mei‐Mei Liu, Chang‐Hao Wu, Jie‐Ying Rao, Qun‐Xian Li, Jing Cancer Med Clinical Cancer Research OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical cancer (LACC). METHODS: Data of 347 LACC patients were retrospectively reviewed. Receiver operating characteristic (ROC) curves were constructed, and areas under the curves (AUCs) were compared to evaluate the ability to predict complete response (CR) following NACT. Patients were stratified into groups with low and high levels of SCCA and FBG and combined into low‐ or high‐SCCA and low‐ or high‐FBG groups. Cox regression analysis was performed to identify determinants of recurrence‐free survival (RFS) and overall survival (OS). RESULTS: The AUCs were 0.70, 0.68, and 0.66 for SCCA, FBG, and a combination of SCCA and FBG for predicting CR following NACT, respectively; however, the differences among AUCs were not significant (P = .496). Pretreatment SCCA and FBG levels were identified as independent predictors of RFS and OS. The high‐SCCA/high‐FBG group showed significantly worse prognosis than the low‐SCCA/low‐FBG group. After adjusting for other variables, high‐SCCA/high‐FBG remained independently associated with an increased risk of tumor recurrence and death. CONCLUSION: SCCA, FBG, and a combination of SCCA and FBG could acceptably predict CR following NACT. Pretreatment SCCA and FBG levels were independent prognostic factors. The combination of SCCA and FBG levels refined the prognostic stratification of LACC patients, which allowed the group of patients with the highest risk of recurrence and death to be identified. John Wiley and Sons Inc. 2019-07-16 /pmc/articles/PMC6718550/ /pubmed/31310455 http://dx.doi.org/10.1002/cam4.2414 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Wu, Miao‐Fang
Guan, Mei‐Mei
Liu, Chang‐Hao
Wu, Jie‐Ying
Rao, Qun‐Xian
Li, Jing
The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title_full The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title_fullStr The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title_full_unstemmed The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title_short The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
title_sort added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718550/
https://www.ncbi.nlm.nih.gov/pubmed/31310455
http://dx.doi.org/10.1002/cam4.2414
work_keys_str_mv AT wumiaofang theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT guanmeimei theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT liuchanghao theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT wujieying theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT raoqunxian theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT lijing theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT wumiaofang addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT guanmeimei addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT liuchanghao addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT wujieying addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT raoqunxian addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy
AT lijing addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy